KANTAR HEALTH BLOG

kh_blog_hero_1600px
  • With the handballing of the brand from Access to Marketing to Sales, ownership of the brand is often disconnected resulting in opportunity unrealized. Today, the world is far more complex and there is greater realization by brand owners that decision making is not at all linear, rational and controlled.
  • A strong brand is not built on a successful launch alone, but also navigating through often complex challenges to maximize the brand's potential across the product lifecycle.
  • Kantar Health research has found that real world data is starting to significantly impact the way market research is performed, and this impact will continue to increase as market researchers become even more comfortable with this resource.
  • The Evolution of Brands

    by Mark Sales  |  Jul 5, 2017
    Brands evolve; they have to and always will. Mark Sales says he can't think of a single corporate or product brand that hasn't followed Darwin's theory of evolution by natural selection. He discusses two types of brands in this blog, both close to his heart and both with more in common than you may think.
  • ASCO Annual Meeting 2017 - Approximately a quarter of breast cancer patients are classified as HER2-positive, according to Kantar Health’s 2016 Treatment Architecture data. Effective targeted agents for the HER2 receptor, such as Herceptin (trastuzumab; Roche) and Perjeta (pertuzumab; Roche), have been developed for this particular patient segment and have greatly improved clinical outcomes for these patients. APHINITY did meet its primary endpoint showing that addition of Perjeta to Herceptin and chemotherapy as adjuvant treatment achieved a statistically significant improvement in IDFS. These data suggest that the triplet may become an option for adjuvant treatment of HER2+ early breast cancer.
More than one Google Analytics scripts are registered. Please verify your pages and templates.